Conexeu Sciences Inc. (CNXU): Unregistered Sales of Equity Securities

Turn Therapeutics (TTRX) rose over 20% after interim Phase 2 results for GX-03 in atopic dermatitis, with 92.6% achieving EASI-50 at 4 weeks. Conexeu (CNXU) gained ~19% on preclinical B.R.E.A.S.T. bioprinting progress. Rallybio (RLYB) jumped on plans to acquire Avenzo via a $215M investment. LIXTE (LIXT) surged on an AI energy pivot; Quanterix (QTRX) rose on insider SEC filing.

Conexeu Sciences (Nasdaq: CNXU) said it has started a preclinical development program for its B.R.E.A.S.T.™ 3D-printed bioregenerative breast matrix at the Wake Forest Institute for Regenerative Medicine (WFIRM). The study will assess durability, host tissue integration and resorbability of its CXU™ matrix platform, using WFIRM’s bioprinting infrastructure.

First Phosphate Corp. (PHOS) may face reduced equity dilution after Noble Capital Markets noted potential lower funding needs for its Bégin-Lamarche project, supported by Swiss Export Risk Insurance (SERV) and other financing. SERV could provide up to US$212.5 million, reducing the equity requirement to about US$82.5 million. Noble maintains an Outperform rating and $25.50 price target.

Aon raised $13.75 billion in senior notes, guaranteed by its subsidiaries, with maturities from 2029 to 2056 and coupons ranging from 5.350% to 6.450%. The funds, approximately $13.4 billion after expenses, will support the USI Advantage Corp. acquisition and general corporate purposes. The notes include redemption protections tied to the deal's completion.

Burford Capital (BUR) priced $300M of 8% senior secured notes due 2029 to refinance $400M of 6.25% unsecured notes due 2028. The move aims to reduce debt and extend maturity, but increases borrowing costs and pledges collateral. Success depends on future cash collections and investment performance.

Agree Realty Corp (NYSE: ADC) announced a $400M bond offering at 5.650% coupon, maturing in 2036. Shares rose 0.03% to $68.16. ADC offers a 4.64% dividend yield but has a high payout ratio of 1.65. GuruFocus values ADC 14.1% undervalued with a GF Score of 87/100. Insiders and gurus show confidence with recent purchases.